BC
Boxer Capital Portfolio holdings
AUM
$2.04B
This Quarter Return
+30.1%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$935M
AUM Growth
+$935M
(+71%)
Cap. Flow
+$250M
Cap. Flow
% of AUM
26.77%
Top 10 Holdings %
Top 10 Hldgs %
69.63%
Holding
34
New
8
Increased
14
Reduced
2
Closed
2
Top Buys
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$46.1M |
| 2 |
Wave Life Sciences
WVE
|
$32M |
| 3 |
DBVT
DBV Technologies
DBVT
|
$23.5M |
| 4 |
PTC Therapeutics
PTCT
|
$22.9M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$22.1M |
Top Sells
| 1 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$10.3M |
| 2 |
ARDM
Aradigm Corp Common Stock
ARDM
|
$6.7M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$6.08M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
$360K |
Sector Composition
| 1 | Healthcare | 94.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
| $111M | 11.87% | 900,000 +75,000 | +9% | +$9.27M |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $106M | 11.3% | 630,000 +30,000 | +5% | +$5.04M |
|
|
3
PTC Therapeutics
PTCT
$3.92B
| $70.2M | 7.49% | 2,600,000 +850,000 | +49% | +$22.9M |
|
4
Esperion Therapeutics
ESPR
$448M
| $65.1M | 6.95% | 900,000 +100,000 | +13% | +$7.23M |
|
|
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $59.9M | 6.39% | 2,826,938 +100,000 | +4% | +$2.12M |
|
6
MacroGenics
MGNX
$112M
| $55.4M | 5.91% | 2,200,000 | – | – |
|
|
7
Wave Life Sciences
WVE
$1.53B
| $54.1M | 5.77% | 1,350,000 +800,000 | +145% | +$32M |
|
|
LOXO
8
DELISTED
Loxo Oncology, Inc
LOXO
| $46.1M | 4.93% | +400,000 | New | +$46.1M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $42.1M | 4.5% | 1,372,510 | – | – |
|
|
MDCO
10
DELISTED
Medicines Co
MDCO
| $41.2M | 4.39% | 1,250,000 +500,000 | +67% | +$16.5M |
|
11
Rocket Pharmaceuticals
RCKT
$354M
| $36.9M | 3.93% | 1,966,051 +966,051 | +97% | +$18.1M |
|
|
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
| $35.2M | 3.76% | 2,712,986 +1,700,000 | +168% | +$22.1M |
|
|
ONCT
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $28.2M | 3.01% | 1,590,000 +1,024,709 | +181% | +$18.2M |
|
|
GTHX
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $24.5M | 2.61% | 660,000 +30,821 | +5% | +$1.14M |
|
|
DBVT
15
DBV Technologies
DBVT
$264M
| $23.5M | 2.51% | +1,020,000 | New | +$23.5M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $22.9M | 2.45% | 250,000 | – | – |
|
17
Rigel Pharmaceuticals
RIGL
$697M
| $18.2M | 1.94% | 5,140,000 +2,000,000 | +64% | +$7.08M |
|
18
Kura Oncology
KURA
$686M
| $15.8M | 1.69% | 844,789 | – | – |
|
19
Viking Therapeutics
VKTX
$3.04B
| $13.9M | 1.49% | +3,186,000 | New | +$13.9M |
|
|
20
Ionis Pharmaceuticals
IONS
$6.79B
| $13.8M | 1.47% | 312,000 -138,000 | -31% | -$6.08M |
|
21
Neurogene
NGNE
$264M
| $10.5M | 1.12% | 747,500 +435,000 | +139% | +$6.12M |
|
|
LJPC
22
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $7.97M | 0.85% | 267,500 | – | – |
|
|
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.67M | 0.71% | +325,000 | New | +$6.67M |
|
|
VIRX
24
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $5.78M | 0.62% | 2,125,000 +800,000 | +60% | +$2.18M |
|
25
Solid Biosciences
SLDB
$427M
| $5.63M | 0.6% | +750,000 | New | +$5.63M |
|